Biomarker development in Sturge-Weber syndrome

Area of Science:

• Genetics and Neurology
• Rare Disease Research
• Biomarker Development

Background:

• Sturge-Weber Syndrome (SWS) is a congenital neurovascular disorder linked to the R183Q GNAQ gene mutation.
• It presents with diverse clinical features affecting the brain, skin, and eyes, including port-wine birthmarks, glaucoma, and seizures.
• Effective management and early identification are crucial for preventing neurological decline.

Purpose of the Study:

• To review current, ongoing, and future research on biomarkers for Sturge-Weber Syndrome.
• To highlight the role of biomarkers in early diagnosis, prognosis, and monitoring treatment response.
• To explore the potential of biomarkers for presymptomatic interventions in infants with SWS.

Main Methods:

• Comprehensive literature review of SWS biomarker studies over the past 25 years.
• Analysis of biomarker development for diagnosis, prognosis, and treatment monitoring.
• Discussion of emerging trends and future directions in SWS biomarker research.

Main Results:

• Biomarkers have been developed over the last 25 years to aid in the early diagnosis and prognosis of SWS.
• These biomarkers facilitate monitoring of clinical status and response to treatment.
• Advancements in biomarker research hold promise for enabling presymptomatic treatment strategies.

Conclusions:

• Biomarkers are essential tools for improving outcomes in Sturge-Weber Syndrome.
• Future research integrating biomarkers with clinical data and machine learning can advance rare disease understanding.
• Early identification and intervention, potentially guided by biomarkers, are key to managing SWS.